| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/10/2008 | CN101319207A Site-directed mutagenesis genetic engineering batroxobin and uses thereof |
| 12/10/2008 | CN101319007A Design and synthesis of novel antimicrobial peptide with high bacteriostatic activity |
| 12/10/2008 | CN101318995A Substituted tetrahydro-isoquinoline isoquinolinium compound, preparation method and application thereof |
| 12/10/2008 | CN101318994A Substituted tetrahydro-isoquinoline-3-carboxylic acid compound, preparation method and application thereof |
| 12/10/2008 | CN101318993A Hybridized peptide with 3S-tetrahydrochysene-beta-carboline-3-carboxylic acid as connecting arm, preparation method and application thereof |
| 12/10/2008 | CN101318992A Complete-basic amino acid oligopeptide, copper complex, synthesis method, self-assembly and application thereof |
| 12/10/2008 | CN101318019A Compositions and methods for the therapy of inflammatory bowel disease |
| 12/10/2008 | CN101318014A Pregnancy promoting liquid for mammalian |
| 12/10/2008 | CN101318013A Uses of IL-4 in preparing medicament composition for treating chronic hepatic fibrosis |
| 12/10/2008 | CN101318012A Application of beta-inhibited protein 1 in governing survival and autoimmunity of T cell |
| 12/10/2008 | CN101318011A Pentapeptide nose spraying agent for thymus gland, preparation method and application thereof |
| 12/10/2008 | CN101317855A Autologous or homologous coagulant produced from anticoagulated whole blood |
| 12/10/2008 | CN100441688C Lim mineralization protein splice variants |
| 12/10/2008 | CN100441596C Deletion type human interleukin 11 microvariant |
| 12/10/2008 | CN100441595C Novel peptides that bind to the erythropoietin receptor |
| 12/10/2008 | CN100441594C Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 12/10/2008 | CN100441223C Human papilloma virus treatment |
| 12/10/2008 | CN100441222C Application of compound PS-341 in preparation of medicine for treating acute pulp leucocythemia |
| 12/10/2008 | CN100441221C Method of reducing side effects of chemotherapy in cancer patient |
| 12/10/2008 | CN100441220C Composition containing dipeptide of histidine and alanine for reducing uric acid |
| 12/10/2008 | CN100441199C Spleen extracts, its preparation method and use |
| 12/09/2008 | US7462704 use of RL9/RL10 protein and the polynucleotides encoding RL9/RL10 protein, e.g., in diagnosing and treating tumor, as well as the pharmaceutical composition containing RL9/RL10 protein or the antibody against it |
| 12/09/2008 | US7462703 For use in gene therapy |
| 12/09/2008 | US7462700 Vectors and host cells encoding and expressing canine RANKL polypeptide are provided, as well as antibodies that bind to RANKL and that inhibit RANKL activity |
| 12/09/2008 | US7462699 Using presence of 60 amino acid botulinum polypeptide as evaluative tool in monitoring and prediciting efficacy of treatment protocols for treatment of clostridial infection |
| 12/09/2008 | US7462694 C-terminally truncated non-cytotoxic PAP mutants |
| 12/09/2008 | US7462691 Prostate stem cell antigen (PSCA) tumor antigen for use in diagnosis, prevention and treatment of prostate cancers |
| 12/09/2008 | US7462688 Peptides for diagnostic and therapeutic methods for celiac sprue |
| 12/09/2008 | US7462687 Prodrugs of vancomycin with hydrolysis resistant polymer linkages |
| 12/09/2008 | US7462602 Anti-scarring ribozymes and methods |
| 12/09/2008 | US7462598 Antimicrobial theta defensins, analogs thereof, and methods of use |
| 12/09/2008 | US7462597 Corticotropin releasing factor 2 receptor agonists |
| 12/09/2008 | US7462596 Pharmaceutical compositions comprising MBL and/or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 mu g/ml protein containing material, wherein mannan binding lectin and |
| 12/09/2008 | US7462595 Methods for treating cancer-related fatigue |
| 12/09/2008 | US7462594 Peptide like compounds for treating coronavirus or aviviridae virus; severe acute respiratory distress syndrome |
| 12/09/2008 | US7462593 Compositions and methods for promoting angiogenesis |
| 12/09/2008 | US7462592 Compositions and methods for polynucleotide delivery |
| 12/09/2008 | US7462486 Monitoring the efficacy of a T Cell Receptor (TCR) Variable peptide for the treatment of autoimmune diseases such as multiple sclerosis, Rheumatoid arthritis, systemic lupus erythematosis, type I diabetes, non-obese diabetes, psoriasis |
| 12/09/2008 | US7462466 Porcine CD59 nucleic acids and cells containing the same |
| 12/09/2008 | US7462465 Nucleic acid encoding KCNB potassium channel |
| 12/09/2008 | US7462462 Peptide capable of binding to nanographite structures |
| 12/09/2008 | US7462459 Bioassays for L-type amino acid transporter 1 (LAT1); screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases |
| 12/09/2008 | US7462447 mutant SH3-binding protein (SH3BP2) nucleic acids, polypeptides, and agents which selectively bind to the mutant SH3BP2 molecules and which do not bind to the wild type SH3BP2 molecules |
| 12/09/2008 | US7462368 Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino]butanoate |
| 12/09/2008 | US7462365 specific combination of excipients exhibits an increase of bioavailability of the polypeptide; namely a sugar and salting-out salt are present in sustained release composition |
| 12/09/2008 | US7462360 for induction of interferon/natural killer cell activity; for treating viral/fungal systemic infections, or oncological diseases |
| 12/09/2008 | US7462357 Polypeptide containing antigen segment; mixture with antibodies; immunostimulants |
| 12/09/2008 | US7462355 Angiogenesis regulation system |
| 12/09/2008 | US7462350 cytokine fusion proteins with an increased therapeutic index; able to bind to more than one type of cytokine receptor expressed on cells |
| 12/09/2008 | US7462349 Preventing or attenuating the progressive chronic inflammation and demyelination resulting from spinal cord by administering beta interferon at dosage and frequency prescribed for treating relapsing-remitting multiple sclerosis |
| 12/09/2008 | CA2415447C Novel .gamma. crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same |
| 12/09/2008 | CA2405553C Bone-strengthening agent, bone-strengthening food and bone-strengthening feed composition |
| 12/09/2008 | CA2387953C Compositions for electroporation |
| 12/09/2008 | CA2301017C Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds |
| 12/09/2008 | CA2183151C Host-vector system for use in gene therapy |
| 12/04/2008 | WO2008148108A1 Calcium channel proteins and uses thereof |
| 12/04/2008 | WO2008148105A1 Endometrial stem cells and methods of making and using same |
| 12/04/2008 | WO2008148068A1 Multicistronic vectors and methods for their design |
| 12/04/2008 | WO2008148023A2 Compositions and methods for treating neurological disorders |
| 12/04/2008 | WO2008147956A2 Toll-like receptor 3 modulators and uses thereof |
| 12/04/2008 | WO2008147556A2 Melanocortin receptor ligands modified with hydantoin |
| 12/04/2008 | WO2008147536A1 Methods and compositions for enhancing proteasome activity |
| 12/04/2008 | WO2008147534A1 Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
| 12/04/2008 | WO2008147426A2 Methods and compositions for immunomodulation |
| 12/04/2008 | WO2008147405A1 O-glycans in the treatment of inflammatory bowel disease and cancers |
| 12/04/2008 | WO2008147304A1 A novel neuroprotective peptide |
| 12/04/2008 | WO2008147187A1 Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
| 12/04/2008 | WO2008147143A2 Immunoglobulin fusion proteins |
| 12/04/2008 | WO2008146907A1 Oral composition |
| 12/04/2008 | WO2008146792A1 Agent for preventing and treating bone fracture and bone disease accompanied by bone mass loss |
| 12/04/2008 | WO2008146710A1 Skin whitening agent |
| 12/04/2008 | WO2008146272A2 Compositions and methods for treating cxcr6/cxcl16 associated diseases |
| 12/04/2008 | WO2008146023A1 Vegf-d mutants and their use |
| 12/04/2008 | WO2008146018A2 Drug delivery system comprising matrix metalloproteinase inhibitors |
| 12/04/2008 | WO2008145989A1 Methods for preparing factor x, activated factor x, inactivated factor x and inactivated factor xa, and pharmaceutical compositions comprising same |
| 12/04/2008 | WO2008145865A2 Mutated hyperthermophilic phosphotriesterases and uses thereof |
| 12/04/2008 | WO2008145855A1 Pharmaceutical and/or cosmetic composition containing a cytochrome c-activating active ingredient |
| 12/04/2008 | WO2008145854A1 Pharmaceutical and/or cosmetic composition containing peptides |
| 12/04/2008 | WO2008145852A1 Pharmaceutical and/or cosmetic composition containing an active ingredient which is antioxidant and which activates cell energy |
| 12/04/2008 | WO2008145851A1 Pharmaceutical and/or cosmetic composition containing peptides |
| 12/04/2008 | WO2008145850A2 Use of an active ingredient derived from amaranth (amaranthus hypochondriacus) for preparing a composition for protecting mitochondria |
| 12/04/2008 | WO2008145849A2 Pharmaceutical and/or cosmetic composition containing aconitase-activating active ingredients |
| 12/04/2008 | WO2008145848A2 Pharmaceutical and/or cosmetic composition containing peptides |
| 12/04/2008 | WO2008145749A1 Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
| 12/04/2008 | WO2008145732A1 Stable non-aqueous pharmaceutical compositions |
| 12/04/2008 | WO2008145603A2 Pharmaceutical compositions comprising telomerase, and uses thereof |
| 12/04/2008 | WO2008145400A2 Mutated structural protein of a parvovirus |
| 12/04/2008 | WO2008145359A1 Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| 12/04/2008 | WO2008145358A1 Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form |
| 12/04/2008 | WO2008145323A1 Pharmaceutical formulation for interferons |
| 12/04/2008 | WO2008145298A1 Reconstituted surfactants having improved properties |
| 12/04/2008 | WO2008145136A1 Stat3 inactivation by inhibition of the folate receptor pathway |
| 12/04/2008 | WO2008145095A2 Amino acid-mineral-peptide complex, especially quantum-mechanically modified, as a medicament for the treatment of dementia diseases |
| 12/04/2008 | WO2008145074A2 Amino acid and nucleic acid sequences and vaccine to control ectoparasite infestations in fish |
| 12/04/2008 | WO2008145013A1 Fusion protein comprising targeting peptide of cd13 and lidamycin |
| 12/04/2008 | WO2008144919A1 Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| 12/04/2008 | WO2008128155A3 SIRTUIN BASED METHODS AND COMPOSITIONS FOR TREATING β- CATENIN-RELATED CONDITIONS |
| 12/04/2008 | WO2008124384A3 Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c |
| 12/04/2008 | WO2008121881A3 INHIBITORS OF NF-ϰB ACTIVITY |
| 12/04/2008 | WO2008116468A3 Mhc peptide complexes and uses thereof in infectious diseases |